Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Aravind Eye Care System and Alcon’s new Coimbatore retina training centre is designed to strengthen vitreoretinal surgical skills and expand access to specialist eye care worldwide. Representative image.
Medical Devices & Diagnostics

Why Alcon and Aravind’s 60-trainee retina surgery hub could matter far beyond Coimbatore

Aravind Eye Care System and Alcon open a Coimbatore retina training hub aimed at expanding vitreoretinal surgical expertise worldwide.

Read More
NADclinic and Geneva College of Longevity Science are linking clinician education with longevity and performance medicine as the sector pushes for stronger evidence, regulatory awareness and responsible clinical practice. Representative image.
Pharma & Biotech

Can NADclinic and GCLS turn longevity medicine’s training gap into a clinical standard?

NADclinic and GCLS are linking postgraduate education with longevity practice as evidence, regulation and clinical governance face scrutiny.

Read More
Harbour BioMed’s antibody discovery platforms and global biopharma partnerships are supporting revenue growth and a seventh consecutive profitable half-year, although the company’s full interim results will determine the durability of its earnings momentum. Representative image.
Pharma & Biotech

Harbour BioMed’s revenue is climbing, but one profit number complicates the growth story

Harbour BioMed expects up to $67 million interim profit as antibody deals lift revenue, but margin trends will shape the next investor debate.

Read More
A spinal specialist reviews thoracic and lumbar imaging as new Regenative Labs research reports improved pain and function scores following umbilical cord tissue allograft applications in 117 patients. Representative image.
Features & Analysis

What Regenative Labs’ 117-patient ProText study reveals about chronic paraspinal degeneration

Regenative Labs reports lower pain and WOMAC scores after paraspinal allograft use, but controlled trials and regulatory clarity remain essential.

Read More
Researchers examine blood-based RNA biomarkers that could eventually support more objective assessment and treatment monitoring for neuropathic pain, as Lilac Biosciences and Soin Neuroscience outline a translational testing roadmap. Representative image.
Pharma & Biotech

Lilac Biosciences and Soin Neuroscience publish RNA biomarker review for neuropathic pain

Lilac Biosciences and Soin Neuroscience map an RNA biomarker path for neuropathic pain, but clinical validation remains the decisive test.

Read More
Velmeni’s FDA-cleared V4D 3D software brings artificial intelligence-assisted segmentation, visualization and analysis to dental cone-beam computed tomography workflows. Representative image.
Medical Devices & Diagnostics

Velmeni just cleared a major dental AI hurdle, but can its 3D CBCT platform win over clinicians?

Velmeni’s FDA-cleared V4D 3D brings AI-assisted CBCT analysis into dental workflows, but adoption now depends on integration and clinical trust.

Read More
ArkBio’s completion of Phase I dosing for AK0406 moves the investigational long-acting influenza prophylaxis candidate into extended safety, pharmacokinetic and immunogenicity follow-up. Representative image.
Pharma & Biotech

What does ArkBio’s AK0406 dosing milestone mean for long-acting influenza prevention?

ArkBio has dosed all Phase I cohorts of AK0406, moving the long-acting influenza prophylaxis candidate into six-month safety follow-up.

Read More
Laminar Pharma’s LAM561 Phase 2b/3 glioblastoma trial has completed its final patient visit, moving the investigational therapy toward a pivotal overall survival readout expected in 2027. Representative image.
Pharma & Biotech

Laminar Pharma has finished patient follow-up. Now one survival result will decide LAM561’s future

Laminar Pharma completes LAM561 trial follow-up as the glioblastoma study advances toward a pivotal overall survival readout in 2027.

Read More
A pharmacist guides a consumer on responsible self-care, reflecting new Economist Enterprise research on why affordable access, trusted health information and clear referral pathways are essential for integrating self-care into healthcare systems. Representative image.
Features & Analysis

Bayer-backed self-care research highlights referral, affordability and health literacy gaps

Bayer-backed research says self-care can ease health-system strain, but only with safeguards, affordable access and clear referral pathways.

Read More
A biotechnology researcher conducts precision laboratory testing as Thyora Therapeutics advances its next-generation covalent drug discovery platform built around bicyclobutane chemistry, chemoproteomics and oncology-focused medicine development. Representative image.
Pharma & Biotech

Can Thyora Therapeutics turn a strained four-carbon ring into safer covalent cancer drugs?

Thyora Therapeutics launches a Science-backed covalent drug platform, but its first candidate and clinical development timeline remain undisclosed.

Read More